The clinical relevance of regulatory T cell (Treg) infiltration in breast cancer (BC) remains controversial, and no recent meta-analysis has been published on this subject. Our aim was to identify the precise relationship between Tregs and the prognosis and clinic-pathological features of BC. Eligible articles were identified with a MEDLINE database search over a period up to March 2015. Our meta-analysis was performed using STATA software 11.0 and Review Manager 5.3. The correlations between Treg infiltration and clinico-pathological features and BC prognosis were analyzed. Subgroup and sensitivity analyses, as well as meta-regression, were conducted. Eighteen published studies (including 8,562 patients) were eligible. Overall survival (OS) and disease-, recurrence-, and progression-free survival (DFS/RFS/PFS) were correlated with Treg infiltration (OR=2.03 (95% CI, 1.40-2.95; P=0.000) and 1.48 (95% CI, 1.00-2.19; P=0.050), respectively), including 3-, 5-, and 10-year mortality rates. In addition, low Treg infiltration was present in estrogen receptor (ER)-positive tumors (P=0.000), progesterone receptor (PR)-positive tumors (P=0.003), Her2-negative tumors (P=0.000) and histological grade I/II tumors (P=0.001). No publication bias was observed with the exception of OS. Subgroup analysis suggested that the mortality rate of the high Treg infiltration subgroup was increased compared with the low Treg infiltration subgroup among ER-positive patients. Treg infiltration indicated a poorer prognosis for BC and is related to ER, PR, and Her2 status and histological grade. Thus, Treg infiltration could help predict outcomes and guide clinical therapy.
Breast cancer (BC) is the most common cancer in women, with over 231,840 new cases and 40,290 deaths estimated to have occurred thus far in 2015 [1] . In recent decades, despite earlier detection and more effective treatment approaches, which have improved the survival rate, current data indicate that advanced malignant disease remains far from being therapeutically controllable. In addition, traditional therapy, including surgery, radiation, and chemotherapy, often cause various side effects and fail to remove the tumor completely [2] . Immunotherapy is a promising approach to treating patients with invasive and metastatic BC [3, 4] . However, the immunosuppressive microenvironments induced by regulatory T cells (Treg) in BC present major barriers to successful antitumor immunotherapy [3, 4] .
Tregs, which typically express CD25, are naturally present in the immune system, accounting for 5 to 10% of CD4 + T cells. The forkhead/winged helix transcription factor gene FOXP3 is expressed by Tregs and has been considered a key regulatory gene for the development and function of Tregs [5] . Tregs are important in the control of immune responses by suppressing T cell proliferation and cytokine production and serve as regulatory factors in the tumor microenvironment [6, 7] . Tregs exhibit prognostic value in patients with gastrointestinal cancers and hepatocellular carcinoma [8, 9] and are associated with an unfavorable prognosis. This value is based on their capacity to inhibit antitumor immunity. However, high tumor infiltration by Tregs can improve survival in some tumors [10] [11] [12] . The value of Tregs in BC remains controversial. Some studies have not observed any correlation between Treg infiltration and prognosis [13, 14] . In contrast, other studies have found associations with a poor response to chemotherapy and poor clinical outcomes in BC patients [15, 16] . In addition, high Treg numbers are associated with Treg marker, Treg staining location, duration of follow-up, cutoff point, data collection methods, survival analysis and clinico-pathological parameters.
Study quality and risk of bias assessment. Study quality was assessed with an established form, which was first developed by Hayes [21] and used by McShane [22] . The evaluation contents are provided in Supplementary Table 1 and were scored on a scale from 0 to 8.
Definition of prognostic outcomes and subgroup analyses. OS was defined as the time from surgery until death. BCSS was defined as the time from the initial diagnosis of BC to death attributed to BC. RFS was defined as the time from the diagnosis of BC to any type of relapse of the disease. DFS was defined as the interval between the initial primary diagnosis of BC and the first relapse or death. PFS was the duration from diagnosis until the first BC progression, death from any cause, or the final follow-up.
The endpoint/outcome measures extracted or calculated were the HRs and their 95% CIs for OS, RFS, DFS, PFS or BCSS, and the events/total events for age, tumor size, ER status, PR status, Her2 status, lymph node metastasis status, Ki67 expression, P53 expression, histological grade, distant metastasis and vascular invasion. Given that various studies have used different definitions for Tregs, we considered HR as the risk ratio between tumors with positive/rich Treg infiltration versus those with no/low Treg infiltration. HR estimates (with the corresponding 95% CIs) for a high density over a low density of Tregs and the HR cutoff point were obtained.
The most frequently used cutoff values for the high versus low/present versus absent density of Tregs were the median (n=11). The values were calculated using several semi-quantitative methods, including X-tile software (n=4) and others (n=3). We also conducted subgroup analyses to investigate the associations between prognostic outcomes (OS, BCSS, RFS, PFS and DFS) and Treg status in different ER-status BC patients (ER positive or ER negative).
Statistical analysis. For time-to-event outcomes, we used HRs and their 95% CIs to estimate the association between Tregs and prognosis. If the survival or mortality rate was not directly available, the 3-, 5-, and 10-year survival data extracted from Kaplan-Meier curves were read by the Engauge Digitizer version 4.1 (http://digitizer.sourceforge.net/) as described previously [23] . Two independent researchers performed the process to reduce inaccuracies in the extracted survival rates (y. W. and R. z. z.). Inter-study heterogeneity was quantified using the I 2 statistic, with an I 2 value=50% indicating substantial heterogeneity, which was calculated as a pooled HR using the Mantel-Haenszel method for a random-effects model. We did not pool results for other outcomes given the small number of studies, heterogeneity between studies, or insufficient reporting. Reasons for statistical heterogeneity were explored through subgroup analysis, meta-regression or sensitivity analyses (when I 2 value>75%), the latter of which was also used to assess the impact of study quality. Publication bias was evaluated using Egger's plots and Begg's funnel plots because studies with positive results are more likely to be published than studies with negative results. All of the P-values were two-sided, and P<0.05 was considered statistically significant for all of the analyses, with the exception of publication bias, for which P<0.10 was considered significant [24] . All of the statistical calculations were performed using STATA 11.0 (StatCorp, College Station, TX, USA) and Revman 5.3 (Nordic Cochran Centre, Copenhagen, Denmark).
Results
Description of the studies. The flowchart for our search strategy is presented in Fig. 1 .
Study characteristics and quality. The baseline characteristics of each study are summarized in Supplementary [33] ). Th e majority of the studies were performed in Asia (n=8). Other studies were conducted in Europe (n=7) and North America (n=3). Th e total sample size from all studies was 8,562, with a mean of 476 patients (ranging from 60 to 3,276 patients). All studies were published between 2006 and 2014. Th e qualities of all the eligible studies are presented in Supplementary Table 1 . Th e median fi nal score of the studies was 6. Impact of Treg infi ltration on OS and BCSS. Th e relationship between Treg infi ltration and BC prognosis is illustrated in Fig. 2 . HRs for OS were available in 5 studies. Th e pooled HR revealed a signifi cantly increased risk of mortality in the high Treg group (OR, 2.03; 95% CI, 1.40-2.95; P=0.000 and I 2 =10.80%, fi xed eff ect; Fig. 2A ). Th en, we extracted overall survival data during follow-up at 3, 5, and 10 years aft er surgical resection from the survival curves of 8 articles. Th e overall mortality rate during the 3-year follow-up was signifi cantly increased in the high Treg infi ltration patients compared with the low Treg infi ltration patients, with a combined RR of 2.44 (n=8; 95% CI, 1.51-3.96, P=0.000; Fig. 2B ). Subgroup analysis revealed that the geographic region potentially caused the heterogeneity (data not shown). Th e overall mortality rate during the 5-year follow-up was signifi cantly increased in the high Treg infi ltration patients, with a combined risk ratio (RR) of 2.40 (n=7; 95% CI, 1.47-3.93, P=0.000; Fig. 2C ). However, no statistically signifi cant survival diff erence was noted at 10 years (95% CI, 0.97-2.67, P=0.065; Fig. 2D ) possibly due to the small number of studies (Supplementary Table 3 ). HRs for BSCC were available in only 3 studies. Th e pooled HR revealed a slightly increased risk of mortality in the patients with high Treg infi ltration (OR, 1.05; 95% CI, 0.82-1.35; Fig. 3A ), but this fi nding did not reach statistical signifi cance (P=0.698). However, the mortality rate during the 3-, 5-, and 10-year follow-up was signifi cantly increased in the high Treg infi ltration patients (P<0.05; Fig. 3B-D; (Supplementary Table 4) .
Impact of Treg infi ltration on RFS/DFS/PFS.
Given the relatively small number of studies with endpoints of PFS, RFS or DFS, we performed a pooled analysis of these three indicators. HRs for RFS/DFS/PFS were available in 8 studies. Th e pooled HR exhibited a signifi cantly increased risk of mortality in the high Treg group (OR, 1.48; 95% CI, 1.00-2.19; P=0.050; Fig. 4A) .
Th e mortality rate during the 3-year follow-up period was signifi cantly increased in the high Treg infi ltration patients compared with the low Treg infi ltration patients, with a combined RR of 1.93 (95% CI, 1.16-3.23, P=0.012; Fig. 4B) . Th e mortality rate during the 5-year follow-up period was signifi cantly increased in the high Treg infi ltration patients, with a combined RR of 1.86 (95% CI, 1.64-2.11, P=0.000; Fig.  4C ). Only one study provided data on 10-year RFS survival, so these data were not included in the meta-analysis [16] (Supplementary Table 5 ).
Meta-analysis based on ER status. Patients with diff erent ER status were divided into subgroups. We pooled the analysis of the two end points OS and BCSS because relatively few studies reported this information.
In ER-positive patients, HRs for BSCC and OS were available in 4 studies. Th e pooled HR revealed that the risk of mortality did not signifi cantly diff er between the two Treg infi ltration groups (OR, 1.38 1; 95% CI, 0.91-2.09, P=0.13). However, the BCSS/OS mortality rate at the 3-, 5-, and 10-year follow-up was signifi cantly increased in the high Treg infi ltration patients (3 years: RR, 2.04, 1; 95% CI, 1.16-3.61, P=0.014; 5 years: RR, 2.13, 1; 95% CI, 1.49-3.04, P=0.000; 10 years: RR, 1.38, 1; 95% CI, 1.22-1.57, P=0.000) (Supplementary Table 6 ).
HRs for RFS/DFS/PFS were available in 3 studies. Th e pooled HR revealed that the risk of mortality did not significantly diff er between the Treg infi ltration groups (OR, 2.16 1; 95% CI, 0.85-5.48, P=0.104). Th e RFS/DFS/PFS rate during the 3-or 5-year follow-up was signifi cantly reduced in the high Treg infi ltration patients compared with the low Treg infi ltration patients (3 years: RR, 2.74; 95% CI, 1.40-5.35; 5 years: RR, 1.82; 95% CI, 1.14-2.89, P<0.05). Only one paper provided the 10-year RFS; thus, this statistic was not included in the meta-analysis [16] (Supplementary Table 7 ).
In ER-negative patients, we did not identify any signifi cant diff erence between the Treg infi ltration groups regarding the BCSS/OS rate or the RFS/DFS/PFS rate at 3, 5, or 10 years (Table 1; detailed in Supplementary Table 8 and Table 9 ).
Correlations of Treg infiltration with clinico-pathological parameters. To gain further insight into the value of Treg infi ltration as an eff ective biomarker, we investigated the association between low Treg infi ltration and various clinico- (Table 2; detailed in Supplementary  Table 10 ). Treg infi ltration was not associated with specifi c clinical parameters for BC, such as age (<50, ≥50), tumor size (≤2 cm, >2 cm), Ki67 status (low, high), distant metastasis (negative, positive), P53 status, vascular invasion, or lymphatic metastasis. However, BCs with low Treg infi ltration were positively associated with PR-positive status (pooled RR=0.66, 95% CI: 0.51-0.87, P=0.003 and I 2 =91.8%, random eff ect), ERpositive status (pooled RR=0.54, 95% CI: 0.44-0.66, P=0.000 and I 2 =83.7%, random eff ect), Her2-negative status (pooled RR=1.08, 95% CI: 1.04-1.12, P=0.000 and I 2 =63.1%, random eff ect), and histological grade I or II (pooled RR=1.35, 95% CI: 1.14-1.59, P=0.001 and I 2 =78.2%, random eff ect). To investigate the observed heterogeneity (I 2 >75%) in the analyses of clinico-pathological parameters, we performed a set of meta-regressions to determine to what extent the eff ects of clinical variables, such as publication year, continent (Asia, Europe or other), sample size (n≤200 or n>200) and cutoff method (median or other), could explain the heterogeneity of ER, PR and histological grade. Th e value of tau-squared decreased from 0.1082 to 0.0942 for ER status, 0.1352 to 0.06782 for PR status, and 0.03567 to 0.001641 for histological grade, which could partly explain the heterogeneity.
Sensitivity analysis and publication bias. To evaluate the infl uence of single studies on the pooled HRs, we performed a sensitivity analysis by estimating the average HR in the absence of each study. Th e results indicated that no individual studies signifi cantly infl uenced the pooled HRs except that Liu et al. 2011 [18] infl uenced the DFS/RFS/PFS and 5-year DFS/ RFS/PFS and Liu et al. 2014 [20] (Fig. 5) .
Discussion
In recent years, the prognosis of patients with BC has improved remarkably, thanks to a variety of treatments, in- cluding surgical resection, adjuvant chemotherapy, hormonal therapy, and radiation therapy. However, the problems of recurrence, metastasis, and drug resistance have not been resolved, and the causes and mechanisms of the above phenomena have not been clarified. Although several risk factors for the development of BC have been evaluated, this is a field of ongoing investigation. Treg infiltration is a known risk factor for cancer incidence and mortality. This study is the first comprehensive meta-analysis to determine the significance of Treg infiltration in BC. The current literature provides a definitive association between Treg infiltration and outcome and clinico-pathological factors of BC. Our study revealed several points worth discussing.
First, our study confirmed the prognostic value of Treg infiltration in BC on OS, PFS/DFS/RFS and BCSS. Patients with Treg infiltration exhibited poorer OS, PFS/DFS/RFS or BCSS compared with patients who lacked Tregs. How does Treg infiltration account for the poor prognosis in BC? Treg cells are found at high concentrations in various types of tumor tissues, such as the lung, liver, pancreas, gastrointestinal tract, BC and malignant melanoma and are associated with poor prognosis in ovarian, breast, and gastric cancers [34] . Tregs in cancer patients can recognize a broad range of tumor antigens, including survivin and Ny-ESO-1, and can suppress tumor antigen-specific T cells [35] . Emerging evidence suggests that Tregs may exhibit specialized functions that affect both angiogenesis and metastasis within the tumor environment. Under hypoxic conditions, Tregs produce vascular endothelial growth factor A (VEGFA), promoting the differentiation of endothelial cells and inducing angiogenesis [36] . Tregs also play a role in BC metastasis by expressing RANK ligand (RANKL) [37] . A growing number of chemokine-receptor axes, including CCL22 and its receptor CCR4 [38] , have been implicated in the trafficking of Tregs to different types of cancer [39] . CXCR4 and its chemokine ligand 12 (CXCL12) are two key factors in BC metastasis [40] . Therefore, Tregs could be a marker for poor BC prognosis.
In our study, Treg infiltration was linked to ER status, PR status, Her2 status and histological grade. Tregs are more prone to infiltrate in BC patients with ER negativity, PR negativity, HER2 positivity and histological grade III. ER, PR, and HER2/ neu are the most important tissue markers used in the management of BC in the adjuvant treatment and metastatic disease settings. ER-positive BCs are associated with good outcomes and histology. In breast tumors, the ER participates in tumor biology and recurrence patterns [41] . Furthermore, loss of PR expression potentially has an important prognostic effect because ER-positive/PR-negative tumors are more aggressive and associated with a reduced OS rate compared with ER-and PR-positive tumors [42] . Histological grade and Her2 are also prognostic factors for BC [43, 44] , and Her2 overexpression is correlated with increased cell proliferation and motility, angiogenesis and tumor invasiveness.
Considering the importance of ER status for prognosis of BC, we performed subgroup analysis according to ER status. Among ER-positive BC patients, low Treg infiltration patients exhibited a higher survival rate at 3-, 5-, and 10-year followup, but the Cox regression did not reveal any difference. However, among ER-negative BC patients, we observed no significant correlation between Treg infiltration and prognosis, which may have been attributed to the small number of relevant studies included in this analysis.
Our study has several strengths. First, our study is large and is the only study to date to evaluate the association between Treg infiltration and BC outcome. Second, the majority of the studies were of high quality. Third, study-level data for ER status, PR status, Her2 status, histopathological differentiation and tumor size allowed meaningful subset analyses. However, our study also has some limitations. First, the number of included studies was relatively small. Because these 8,562 patients exhibited different TMN stages and received various follow-up treatments, we were unable to assess the potential outliers present in individual studies. Second, the cutoff values differed between studies. The median of molecular marker levels was used as the cutoff between high and low or present and absent in 9 studies. In addition, other studies used different cutoffs, which could have caused heterogeneity among the studies. Third, Treg infiltration in the included studies was measured primarily using IHC, the results of which are strongly dependent upon methodological factors, such as primary antibody and secondary antibody concentrations. Finally, the studies included in this meta-analysis were from Asia, Europe and North America. Distinct location or race differences are believed to exist and could cause publication bias. We could not perform subgroup analysis for survival to explore this influence because few studies offered concrete data.
In conclusion, this meta-analysis indicates a positive association between Treg infiltration and poor outcomes in BC. To make Tregs clinically useful in BC, particularly for prognosis, additional large prospective studies should be conducted.
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